Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure
- Author:
Tommaso Lorenzo PARIGI
1
;
Maria Corina Plaz TORRES
;
Alessio AGHEMO
Author Information
- Publication Type:Review
- Keywords: Hepatitis C virus (HCV); Antivirals; Re-treatment; Sofosbuvir
- MeSH: Antiviral Agents; Financing, Organized; Hepacivirus; Hepatitis C; Hepatitis; Humans; Liver; Liver Diseases; Sofosbuvir; Treatment Failure
- From:Clinical and Molecular Hepatology 2019;25(4):360-365
- CountryRepublic of Korea
- Language:English
- Abstract: Despite the high efficacy of direct acting antivirals (DAAs) not all patients successfully clear hepatitis C virus infection, in fact, approximately 1–3% fail to reach a sustained virological response 12 weeks after end of treatment. DAA failures are characterized by advanced liver disease, specific genotypes/subtypes and resistance associated substitutions to the DAA class they have been treated with. Current European Association for the Study of the Liver guidelines recommend three therapeutic options for such patients. The first is a 12 week course of sofosbuvir (SOF), velpatasvir (VEL) and voxilaprevir (VOX), which has shown to be effective in 90–99% of patients and was granted A1 level recommendation. The second option, reserved for patients who have predictors of failure consists in 12 weeks regimen with glecaprevir (GLE) and pibrentasvir (PIB), effective in 90–97%. Finally, although not supported by published data, for especially difficult to treat patients there should theoretically be a benefit in prolonged combinations of SOF+GLE/PIB or SOF/VEL/VOX±ribavirin. This review presents the latest evidence from both clinical trials and real-life on such therapeutic strategies.
